Search details
1.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36623515
2.
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gynecol Oncol
; 162(1): 163-172, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33867143
3.
Inflammation and breast density among female Chinese immigrants: exploring variations across neighborhoods.
Cancer Causes Control
; 30(10): 1113-1126, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31392546
4.
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer.
BMC Genomics
; 17(1): 811, 2016 10 19.
Article
in English
| MEDLINE | ID: mdl-27756228
5.
PTN signaling: Components and mechanistic insights in human ovarian cancer.
Mol Carcinog
; 54(12): 1772-85, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-25418856
6.
Acculturative stress and inflammation among Chinese immigrant women.
Psychosom Med
; 76(5): 320-6, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24846001
7.
Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma.
Cancers (Basel)
; 15(20)2023 Oct 10.
Article
in English
| MEDLINE | ID: mdl-37894278
8.
First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function.
Cancers (Basel)
; 15(5)2023 Mar 06.
Article
in English
| MEDLINE | ID: mdl-36900405
9.
Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.
Sci Rep
; 13(1): 18341, 2023 10 26.
Article
in English
| MEDLINE | ID: mdl-37884576
10.
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
NPJ Breast Cancer
; 9(1): 10, 2023 Mar 06.
Article
in English
| MEDLINE | ID: mdl-36878909
11.
Proteomic Profiling of Fallopian Tube-Derived Extracellular Vesicles Using a Microfluidic Tissue-on-Chip System.
Bioengineering (Basel)
; 10(4)2023 Mar 27.
Article
in English
| MEDLINE | ID: mdl-37106610
12.
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol
; 127(1): 70-4, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22710075
13.
Combined Exercise and Game-Based Cognitive Training Intervention: Correlative Pilot Study of Neurotrophic and Inflammatory Biomarkers for Women With Breast Cancer.
Cancer Nurs
; 2022 Dec 01.
Article
in English
| MEDLINE | ID: mdl-36542098
14.
Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Cell Oncol (Dordr)
; 44(1): 77-92, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-32910411
15.
WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1.
J Extracell Vesicles
; 10(4): e12067, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33598108
16.
Exploration of biomarkers from a pilot weight management study for men undergoing radical prostatectomy.
Urol Oncol
; 39(8): 495.e7-495.e15, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33563536
17.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Clin Cancer Res
; 27(14): 3896-3904, 2021 07 15.
Article
in English
| MEDLINE | ID: mdl-33602685
18.
Insight into poliovirus genome replication and encapsidation obtained from studies of 3B-3C cleavage site mutants.
J Virol
; 83(18): 9370-87, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19587035
19.
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
J Immunother Cancer
; 8(2)2020 10.
Article
in English
| MEDLINE | ID: mdl-33037114
20.
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Gynecol Oncol
; 113(1): 21-7, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19162309